De Burlo Group’s Integra LifeSciences IART Stock Holding History

De Burlo Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$136K	Hold	14,463	–	–	0.03%	88
2025 Q4	$180K	Hold	14,463	–	–	0.02%	79
2025 Q3	$207K	Hold	14,463	–	–	0.03%	77
2025 Q2	$177K	Hold	14,463	–	–	0.02%	80
2025 Q1	$318K	Hold	14,463	–	–	0.05%	73
2024 Q4	$328K	Hold	14,463	–	–	0.04%	72
2024 Q3	$263K	Hold	14,463	–	–	0.03%	75
2024 Q2	$421K	Hold	14,463	–	–	0.06%	70
2024 Q1	$513K	Hold	14,463	–	–	0.07%	69
2023 Q4	$552K	Hold	14,463	–	–	0.1%	71
2023 Q3	$552K	Hold	14,463	–	–	0.1%	71
2023 Q2	$595K	Hold	14,463	–	–	0.1%	73
2023 Q1	$830K	Hold	14,463	–	–	0.16%	70
2022 Q4	$811K	Hold	14,463	–	–	0.18%	61
2022 Q3	$613K	Buy	+14,463	New	+$741K	0.15%	63
2022 Q2	–	Sell	-14,463	Closed	-$929K	–	144
2022 Q1	$929K	Hold	14,463	–	–	0.17%	61
2021 Q4	$969K	Sell	14,463 -145	-1%	-$9.81K	0.14%	73
2021 Q3	$1M	Hold	14,608	–	–	0.16%	69
2021 Q2	$997K	Hold	14,608	–	–	0.16%	66
2021 Q1	$1.01M	Hold	14,608	–	–	0.18%	65
2020 Q4	$948K	Hold	14,608	–	–	0.16%	64
2020 Q3	$690K	Buy	14,608 +210	+1%	+$9.99K	0.13%	63
2020 Q2	$643K	Hold	14,398	–	–	0.18%	50
2020 Q1	$643K	Sell	14,398 -100	-0.7%	-$5.25K	0.18%	50
2019 Q4	$845K	Hold	14,498	–	–	0.17%	62
2019 Q3	$871K	Hold	14,498	–	–	0.2%	58
2019 Q2	$810K	Hold	14,498	–	–	0.16%	65
2019 Q1	$808K	Buy	14,498 +2,544	+21%	+$130K	0.16%	72
2018 Q4	$539K	Hold	11,954	–	–	0.12%	75
2018 Q3	$787K	Hold	11,954	–	–	0.15%	90
2018 Q2	$769K	Hold	11,954	–	–	0.16%	84
2018 Q1	$661K	Hold	11,954	–	–	0.14%	80
2017 Q4	$572K	Hold	11,954	–	–	0.12%	81
2017 Q3	$603K	Hold	11,954	–	–	0.13%	83
2017 Q2	$651K	Sell	11,954 -100	-0.8%	-$4.78K	0.15%	79
2017 Q1	$507K	Hold	12,054	–	–	0.11%	80
2016 Q4	$517K	Hold	12,054	–	–	0.13%	80
2016 Q3	$497K	Buy	12,054 +1,118	+10%	+$46.8K	0.14%	81
2016 Q2	$436K	Buy	+10,936	New	+$393K	0.11%	79
2016 Q1	–	Sell	-10,936	Closed	-$370K	–	97
2015 Q4	$370K	Hold	10,936	–	–	0.09%	86
2015 Q3	$325K	Sell	10,936 -2,441	-18%	-$76.3K	0.08%	88
2015 Q2	$368K	Hold	13,377	–	–	0.08%	88
2015 Q1	$337K	Hold	13,377	–	–	0.07%	91
2014 Q4	$296K	Hold	13,377	–	–	0.06%	98
2014 Q3	$271K	Hold	13,377	–	–	0.06%	96
2014 Q2	$257K	Hold	13,377	–	–	0.06%	92
2014 Q1	$251K	Hold	13,377	–	–	0.06%	87
2013 Q4	$260K	Hold	13,377	–	–	0.06%	93
2013 Q3	$220K	Hold	13,377	–	–	0.06%	91
2013 Q2	$200K	Buy	+13,377	New	+$196K	0.06%	90

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

De Burlo Group's IART Position: Q1 2026 in Review

De Burlo Group held its Integra LifeSciences (IART) position steady in Q1 2026 at 14,463 shares worth $136K. The position accounts for 0.03% of the portfolio, ranked #88.

De Burlo Group first reported a position in IART in Q2 2013 and has held it in 50 quarters since. The position peaked at $1.01M in Q1 2021. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

De Burlo Group held 14,463 shares of Integra LifeSciences worth $136K as of Q1 2026.
De Burlo Group left its Integra LifeSciences share count unchanged in Q1 2026.
Integra LifeSciences made up 0.03% of De Burlo Group's portfolio in Q1 2026, its #88 holding.
De Burlo Group first reported a position in Integra LifeSciences in Q2 2013 and has held it in 50 quarters since.
De Burlo Group's Integra LifeSciences position peaked at $1.01M in Q1 2021.
201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on De Burlo Group's 13F filing for Q1 2026, filed 14 May 2026.